(Total Views: 494)
Posted On: 02/09/2019 1:32:33 PM
Post# of 72446
Sound reasoning. I'd divide all of your numbers by 2 or 3.
Our royalty rate will likely be in the 6-12% range given our poor bargaining position. Looking at this report, inflammation indications almost never grant 15% and the vast majority are under 10%. Our dire need for upfront cash for development of other indications will only compound this.
https://pharmaintelligence.informa.com/~/medi...report.pdf
The university we licensed Brilacidin from also gets a slice of the pie (10% I think).
I think there will be a deal that will save the company short term but be prepared to be underwhelmed by the terms.
I think Kevetrin is what will propel IPIX to $10+ if we succeed in a phase 2 with the oral dosage. Kevetrin and future B indications (Acne, HS, AD) will be real stock price drivers beyond $5 as we will be able to negotiate much more favorable partnerships.
Our royalty rate will likely be in the 6-12% range given our poor bargaining position. Looking at this report, inflammation indications almost never grant 15% and the vast majority are under 10%. Our dire need for upfront cash for development of other indications will only compound this.
https://pharmaintelligence.informa.com/~/medi...report.pdf
The university we licensed Brilacidin from also gets a slice of the pie (10% I think).
I think there will be a deal that will save the company short term but be prepared to be underwhelmed by the terms.
I think Kevetrin is what will propel IPIX to $10+ if we succeed in a phase 2 with the oral dosage. Kevetrin and future B indications (Acne, HS, AD) will be real stock price drivers beyond $5 as we will be able to negotiate much more favorable partnerships.
(1)
(0)
